Hyalgan (Sodium Hyaluronate)

Hyalgan is indicated for the symptomatic treatment of osteoarthritis in specific joints. It is used when patients require additional relief beyond oral analgesics or physical therapy.

• Knee osteoarthritis with mild to moderate pain and functional limitation.
• Hip osteoarthritis where intra‑articular therapy is appropriate.
• Patients who have contraindications to non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Adjunct to physical rehabilitation programs to improve joint mobility.
• May be considered after failure of conservative measures such as weight management and exercise.

• Sodium hyaluronate injected into the joint space integrates with the existing synovial fluid, restoring its viscoelastic properties. By increasing the concentration of hyaluronic acid, the solution enhances lubrication and shock absorption, reduces friction, and may improve the biomechanical environment of the cartilage, thereby alleviating pain and improving joint function.

Adverse reactions to Hyalgan are generally related to the injection site and systemic responses.

Common

• Transient joint pain or swelling at the injection site.
• Localized warmth or redness.
• Mild stiffness or limited range of motion.
• Low‑grade fever.
• Headache.

Serious

• Severe allergic reaction (anaphylaxis) with rash, itching, or breathing difficulty.
• Joint infection (septic arthritis) presenting with intense pain, fever, and swelling.
• Persistent effusion requiring medical intervention.
• Nerve injury causing numbness or weakness near the injection site.

Before using Hyalgan, certain safety considerations should be reviewed.

• Assess for known hypersensitivity to sodium hyaluronate or any formulation components.
• Avoid intra‑articular injection in joints with active infection or septic arthritis.
• Use caution in patients with a history of severe allergic reactions or anaphylaxis.
• Evaluate bleeding risk; avoid in patients with uncontrolled coagulopathy or on anticoagulants without proper monitoring.
• Pregnancy and lactation status are unknown; consider risk‑benefit ratio.
• Ensure proper aseptic technique to minimize infection risk.
• Monitor for signs of joint effusion or worsening pain after injection.

Hyalgan may interact with other medications or substances that affect joint health or bleeding risk.

Avoid

• Concurrent intra‑articular corticosteroid injections within a short interval, which may increase cartilage damage.
• Use of systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) without monitoring for bleeding at the injection site.

Use with caution

• NSAIDs, as they may mask early signs of joint infection.
• Disease‑modifying osteoarthritis drugs (DMOADs) that could alter joint environment.
• Immunosuppressive agents that could increase infection susceptibility.
• Herbal supplements affecting coagulation (e.g., ginkgo, garlic).